The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization dedicated to providing scientists in the lab the funding they need to make game-changing discoveries in cancer treatments, detection and, ultimately, a cure for all types of cancer. It has distinguished itself by emphasizing long-term, transformative research often overlooked by other major funding sources and/or deemed too risky.

The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs that can potentially save cancer patients’ lives.

The goal of the SPARTA study is to learn if an investigational drug, called APL-101, can help patients with non-small cell lung cancer (NSCLC) or other advanced solid tumors with a genetic alteration in c-Met oncogene (such as amplification, fusion, or EXON 14 skipping mutation). Other advanced solid tumors include, but are not limited to, brain, head and neck, gastric, esophageal, biliary, pancreatic, or colorectal cancer.

Yiviva is launching a research study to investigate whether adding YIV-906 (the study drug), comprised of four naturally derived ingredients (licorice, skullcap, peony, and dates) to sorafenib (a currently available, typical treatment for liver cancer) can increase the length of time patients with hepatocellular carcinoma (HCC) live with their disease before it worsens. The evidence-based study drug is developed from an 1800-year-old Chinese formula.